83-5600-82　A2780 Cells 1vial　300491

特徴

• 概要：A2780 is a human ovarian cancer cell line that was first established in 1972 from a patient with advanced epithelial ovarian cancer.
• The cells were characterized as being sensitive to cisplatin and doxorubicin, two commonly used chemotherapy drugs for ovarian cancer.
• Since its establishment, A2780 has been widely used in cancer research studies, particularly in the development and testing of new cancer treatments.
• Research using A2780 cells has provided valuable insights into the biology of ovarian cancer, including the identification of specific genetic mutations such as TP53 and BRCA1.
• These mutations are associated with increased risk of ovarian cancer and are also found in other types of cancer.
• Additionally, A2780 cells have been used to study the role of angiogenesis, the process by which new blood vessels form, in ovarian cancer progression and to evaluate the efficacy of anti-angiogenic drugs.
• Angiogenesis plays a critical role in the growth and progression of ovarian cancer as it provides oxygen and nutrients for the cancer cells to grow.
• Studies using A2780 cells have demonstrated the overexpression of pro-angiogenic factors such as VEGF and angiopoietin-2, which promote the formation of new blood vessels.
• Additionally, A2780 cells have been used to test the efficacy of anti-angiogenic drugs such as bevacizumab, which target VEGF and inhibit the formation of new blood vessels.
• Furthermore, A2780 cells have been used to evaluate the efficacy of various therapeutic agents, including chemotherapy drugs, targeted therapies such as PARP inhibitors, and immunotherapies.
• In particular, A2780 cells have been used to study the effect of different drug combinations on cancer cell proliferation, apoptosis, and drug resistance.
• Overall, the A2780 cell line has played a significant role in the advancement of ovarian cancer research, providing a valuable tool for understanding the disease and developing new treatments.